LabCorp to acquire prenatal testmaker Sequenom for $371M in cash deal

David King
David King, chairman and CEO of LabCorp.

Laboratory Corporation of America Holdings ($LH), a global diagnostics company, will buy prenatal testmaker Sequenom ($SQNM) for $371 million in cash.

Under terms of the agreement, LabCorp will acquire all of Sequenom in a cash tender offer for $2.40 per share, or an equity value of $302 million, the company said. That represents a total enterprise value of approximately $371 million, which includes net indebtedness.

The transaction, which is subject to customary closing conditions and shareholder approval, will be done through an acquisition subsidiary, Savoy Acquisition, setup by LabCorp. The deal is expected to be completed by the end of the year, the company said.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

"This is exactly the kind of strategic acquisition that LabCorp seeks,” David King, chairman and CEO of LabCorp, said in a statement. “Sequenom's proven best-in-class technology and strong research complement LabCorp's extensive women's health offering, providing patients and physicians with one source for the most complete range of testing options in women's health, including NIPT (noninvasive prenatal testing) and reproductive genetics.”

Following a change in leadership last September, Sequenom announced it reached a deal with UnitedHealthcare ($UNH) to offer its carrier screening tests to the insurer's 43 million covered lives. The deal was seen as a big boost for its business, as the contract brought the number of covered lives under Sequenom's diagnostic services to more than 200 million.

LabCorp focuses on diagnostic solutions, getting new medicines to patients faster and developing technology solutions. The company reported net revenue of more than  $8.5 billion in 2015.

JP Morgan is acting as financial adviser to Sequenom for the transaction, and Cooley is providing legal advice. Barclays is acting as financial adviser to LabCorp, and Hogan Lovells is providing legal advice.

- check out the release

Related Articles:
Strategic investors LabCorp, Envision put $15M into remote patient monitoring startup Vivify
Sequenom appoints new CEO amid diversification 
Sequenom unloads Bioscience business for $31M

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.